Saturday, November 16, 2024
spot_imgspot_img

Top 5 This Week

spot_img

Related Posts

Ellzia Pak (triamcinolone acetonide ointment, dimethicone)

What is Ellzia Pak, and how does it work?

Triamcinolone Acetonide Ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

What are the side effects of Ellzia Pak?

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence):

To report SUSPECTED ADVERSE REACTIONS, contact Teligent Pharma, Inc. at 1-856-697-1441, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

What is the dosage for Ellzia Pak?

Apply a thin film to the affected area two to three times daily.

Occlusive Dressing Technique

  • Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions.
  • Apply a thin film of ointment to the lesion, cover with a pliable nonporous film, and seal the edges.
  • If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication.
  • The frequency of changing dressings is best determined on an individual basis.
  • It may be convenient to apply Triamcinolone Acetonide Ointment under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion).
  • When utilizing the 12-hour occlusion regimen, additional ointment should be applied, without occlusion, during the day. Reapplication is essential at each dressing change.

If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

What drugs interact with Ellzia Pak?

No Information Provided

Is Ellzia Pak safe to use while pregnant or breastfeeding?

  • Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels.
  • The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.
  • There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids.
  • Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
  • Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
  • It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk.
  • Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant.
  • Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Popular Articles